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124 Poster Session IIrapamycin, and TGF- b on human Treg cell generation ex vivo.
Normal donor CD4 T cells were isolated by CD4 positive selection
and CD41CD127- cells were isolated by CD127 negative selection
and CD4 positive selection. Relative to total CD4 T cells,
CD41CD127- cells were enriched for the Treg transcription fac-
tor, Foxp3 (n5 8 experiments; P5 0.042); and also had reduced se-
cretion of IL-2 (P5 0.05) and IFN-g (P5 0.03). Both subsets were
expanded using anti-CD3, anti-CD28 co-stimulation and IL-2 6
rapamycin and 6 TGF-b. Relative to culture input of total CD4
cells, input of CD41CD127- cells were potent suppressors at day
12, asmeasured by inhibition of responderT cell proliferation in re-
sponse to allogeneic dendritic cell (DC) stimulation. The enhanced
capacity of CD127 negative selection to generate Tregs occurred
whether expansion was performed in rapamycin (P 5 0.02), TGF-
b (P 5 0.02), or combination of both (P 5 0.01). CD127 negative
selection alone (without rapamycin or TGF-b) was not sufficient
to generate Treg cells, as the resultant product secreted high levels
of IL-2 and IFN-g. In contrast, addition of rapamycin or TGF-b,
and in particular the combination, resulted in a Treg phenotype
as defined by: (1) high Foxp3 expression (50% CD41Foxp31);
(2) reduced Th1 cytokine secretion; and (3) suppressor function in
the allo-MLR. Transwell showed that expanded Treg cell suppres-
sionwas contact dependent.We hypothesized that such suppression
was mediated via modulation of DC function; to address this, Treg
cells and DC were co-cultured, and purified ‘‘conditioned’’ DC
were utilized as the APC source in allo-MLR. Indeed, DC condi-
tioned by Treg cells generated from CD41CD127- enriched cells
and expanded in rapamycin and TGF-b had: (1) significantly re-
duced secretion of IL-6 and TNF-a; (2) increased expression of
the inhibitory molecule PDL1; and (3) greatly reduced allostimula-
tory function; importantly, antibody blockade of DC expression of
PDL1 partially reversed the suppressive DC phenotype. In conclu-
sion, CD127- selction combined with ex vivo expansion in rapamy-
cin and TGF-b generates human Treg cells that inhibit
alloreactivity by modulating DC function. Adotive transfer of
such Tregs has implications in preventing GVHD after haemato-
poietic stem cell transplantation.337
THE PREDICTIVE VALUE OF GENE EXPRESSION PROFILES FOR ACUTE
GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING FOR HEMA-
TOLOGICAL MALIGNANCY
Masmas, T.N.1, Johansen, J.V.2, Friis-Hansen, L.3, Petersen, S.L.1,
Kornblit, B.1, Winther, O.2, Nielsen, F.C.3, Vindelov, L.L.1. 1Allogeneic
Hematopoietic Cell Transplantation Laboratory, Rigshospitalet, Copenha-
gen, Denmark; 2University of Copenhagen, Copenhagen, Denmark;
3Rigshospitalet, Copenhagen, Denmark.
Purpose:To test the hypothesis that global gene expression pro-
files of peripheral bloodmononuclear cells (PBMNC) day114 after
hematopoietic cell transplantation with nonmyeloablative condi-
tioning could predict the later occurrence of acute graft-versus-
host disease (GVHD) grade II-IV. Material: Between March 2000
and Marts 2006, 100 patients with hematological malignancies re-
ceived peripheral blood stem cells from an human leukocyte antigen
identical sibling/mother donor or from a matched unrelated donor
following nonmyeloablative conditioning with low dose fludarabine
and 2Gy of total body irradiation. Post-transplant immunosuppres-
sion consisted of cyclosporine and mycophenolate mofetil. Only
patients with sustained engraftment, who did not experience late-
onset acute GVHD after day 1100 were included; eight patients
were excluded due to graft rejection, three patients due to subopti-
mal RNA or lacking PBMNC samples, and further 15 patients due
to late-onset acute GVHD. Seventy-four patients were then eligible
for microarray analysis.Methods: RNA was precipitated from fro-
zen PBMNC from day114 post-transplant and gene profiling anal-
yses were performed using Human Genome U133 Plus 2.0
GeneChip Array. The array data were normalized, RMA modeled
and asinh transformed in R. The differentially regulated gene ex-
pression between the group of patients developing acute GVHD
before day140,156 and184 post-transplant compared to the pa-
tients never experiencing acute GVHD was identified and formed
the basis for the subsequent principal component analysis (PCA)and classifying models. No patients experienced acute GVHD be-
tween day185 and1100 post-transplant.Results:The patients ex-
periencing acute GVHD by different time points were separated
from the patients never experiencing acute GVHD by the PCA
plot. Furthermore, the best classifying models could separate the
groups correctly in up to 98% of cases. In addition, differentially
regulated genes between the two groups were identified. Conclu-
sion:These data suggest that the pattern of gene expression profiles
early post-transplant is able to predict patients with a high risk of
later occurrence of acute GVHD from those never experiencing
acute GVHD. This knowledge could be exploited to increase the
immunosupression and thus prevent acute GVHD in patients at
risk. Furthermore, candidate genes of interest for the pathogenesis
of acute GVHD have been identified.338
T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR
CELLULAR ANTI-TUMOR IMMUNOTHERAPY
van Loenen, M.M., Griffioen, M., van Egmond, H.M.E.,
Hagedoorn, R.S., Kester, M., Willemze, R., Falkenburg, J.H.F.,
Heemskerk,M.H.M. Leiden UniversityMedical Center, Leiden, Nether-
lands.
T cell receptor (TCR) transfer to engineer tumor specific T cells
may be an alternative strategy for adoptive immunotherapy. For
complete eradication of leukemic cells and to achieve long-term
protection, potent effector T cell function and long-termT cell per-
sistence are necessary. Therefore, we propose to use virus specific T
cells for TCR transfer since such engineered dual specific T cells
can be triggered via their endogenous TCR by latent presence of vi-
ral antigens, improving their long-term persistence. We previously
demonstrated that transfer of the minor histocompatibility antigen
HA-1 and HA-2 TCRs to CMV specific T cells led to the genera-
tion of anti-leukemic T cells with dual specificity. Based on these re-
sults, we developed a clinical grade method for generation of TCR
transferred virus T cells for cellular immunotherapy. Pentamers
combined with clinical grade available anti-biotin magnetic beads
were used to isolate CMV and EBV specific T cells. At day 3 after
isolation, T cells were transduced with multi-cistronic retroviral
vectors encoding the alpha and beta chains of the HA-2TCR linked
by an IRES or 2A-like sequence. Isolation by pentamer-coated
beads led to the generation of T cell lines with high frequencies
(.80%) of virus-specific T cells with 20–40% transduced cells.
The T cells exhibited dual specificity, and tetramer staining corre-
lated with lysis of target cells expressing endogenously-processed
HA-2. We determined whether these cells preserve their dual spec-
ificity upon repetitive stimulation. When frequent encounter of vi-
ral antigens leads to selective survival of TCR transferred T cells
predominantly expressing the CMVTCR incapable of proliferating
via the introduced TCR, persistence in vivo of TCR transferred
CMV T cells capable of controlling minimal residual disease may
fall short. We analyzed the TCR expression and functional activity
of the TCR transferred T cells after repetitive stimulation with
CMV or HA-2. TCR-transferred T cells repetitively stimulated
skewed to T cells predominantly expressing one TCR. However,
this skewing was not due to selective outgrowth, but to change of
TCR make up. This TCR make up appeared to be reversible, and
HA-2 TCR transferred CMV T cells remained their functional ac-
tivity via both TCRs after repetitive stimulation. In a clinical phase
I/II study, the safety, clinical and immunological efficacy of TCR-
transduced virus T cells as cellular anti-tumor immunotherapy
will be investigated.339
INFLIXIMAB COMBINED WITH DACLIZUMAB RESULTS IN A HIGH COM-
PLETE RESPONSE RATE WHEN USED TO TREAT ACUTE STEROID RE-
FRACTORY GRAFT-VERSUS-HOST DISEASE (SR-GVHD)
Srinivasan, R.1, Arrington, J.2, Karpovich, J.2, Donohue, T.2,
Goodwin, R.2, Ramos, C.2, Cook, L.2, Barrett, J.2, Childs, R.2. 1National
Cancer Institute, Bethesda, MD; 2National Heart, Lung and Blood Insti-
tute, Bethesda, MD.
Poster Session II 125There is no effective therapy for patients(pts) who develop SR-
GVHD following allogeneic hematopoietic cell transplanta-
tion(HCT). Cytokines such as IL2 & TNFa have been identified
as mediators of acute GVHD.However, single agent antibody ther-
apy against the IL2 receptor(daclizumab) or TNFa (infliximab) has
only modest activity in SR-GVHD.We hypothesized that concom-
itant blockade of both TNFa& IL2 would be more effective in this
condition than inhibitionof either cytokine alone. Between 2/02 and
10/07, 131 pts with solid tumors(n 5 69), hematologic malignan-
cies(n5 15) or nonmalignant hematologic diseases(n5 47) under-
went nonmyeloablative HCT from a 6/6(n 5 128) or 5/6(n 5 3)
HLA-matched family donor at our institution. Pre-transplant con-
ditioning consisted of cyclophosphamide & fludarabine given alo-
ne(n 5 89) or with ATG(n 5 42). Cyclosporine, plus either
MMF(n 5 45) or MTX(n 5 86) was used as GVHD prophylaxis.
Twenty one pts developed grade 3–4 SR-GVHD(GVHD that did
not improve after$6 days of$1 mg/kg methylprednisolone [MP],
including $3 days of high dose MP) a median of 28 days following
HCT; involved organs included the lower GI tract(n 5 21), liver
(n 5 3) & skin (n 5 7). All pts received daclizumab (1 mg/kg,
days1,4,8,15,22) & infliximab (10 mg/kg, days1,8,15,22). Measures
to minimize the risk of opportunistic infections were rigorously ap-
plied & included aspergillus prophylaxis, empiric broad-spectrum
antibiotics, surveillance blood cultures & a rapid reduction in the
dose of MP (#1 mg/kg). We observed a remarkably high response
rate following therapy, with 19/21(90%) pts experiencing complete
resolution(CR) of GVHD in affected organs. Responses were usu-
ally delayed(median onset 2 weeks) but durable, with all responders
recovering sufficiently for hospital discharge. The most notable
complication associated with therapy was the development of inva-
sive fungal infections in three pts; in two of these, prophylactic anti-
fungal therapy had been prematurely discontinued due to drug
toxicity.Nine patients are alive at the time of this analysis, with ame-
dian survival of 255 days (range 37–1724 d). Four pts died from pro-
gression of their underlying solid tumor, two from complications
related to CMV, & four from complications related to GVHD (in-
cluding three from invasive fungal infections). These data suggest
combined TNFa/IL2 blockade is an effective therapeutic option
for pts with SR-GVHD& highlight the need for aggressive antimi-
crobial prophylaxis in the management of this condition.340
RESPONSE TO STEROIDS AS PRIMARY THERAPY FOR ACUTE GRAFT-
VERSUS-HOST DISEASE (GVHD) IN 280 HEMATOPOIETIC STEM CELL
TRANSPLANT (HSCT) RECIPIENTS: COMPARISON OF UNRELATED DO-
NOR (URD) BONE MARROW (BM) AND UMBILICAL CORD BLOOD (UCB)
MacMillan, M.L., Wagner, J.E., Arora, M., DeFor, T.E., Blazar, B.R.,
Weisdorf, D.J. University of Minnesota, Minneapolis, MN.
Acute GVHD remains a major cause of morbidity and mortality
after allogeneic HSCT. To date, there has been no comparison of
URD HSC sources in terms of response to primary therapy for
acute GVHD. Therefore, we evaluated the response in 280 patients
with grade II-IV acute GVHD, treated with prednisone 60 mg/m2
as initial therapy between 1995–2006 at the University of Minne-
sota. One hundred and thirty-one patients received URD donor
BM, and 149 receivedURDUCB.UCB recipients were more likely
to be: transplanted more recently, have greater HLA disparate
grafts, treated with non-myeloablative conditioning, and receive
CSA/MMF as GVHD prophylaxis. The groups had similar recipi-
ent age, gender, maximum initial acute GVHD grade, and days
from HSCT to acute GVHD. The day 28 response was defined
as the maximum acute GVHD grade (and organ stage) at 28 days
(614 days) of prednisone therapy. Complete response (CR) was de-
fined as resolution of acute GVHD in all organs maintained for 28
days (to day 56) without additional treatment. Partial response (PR)
was defined as improvement of GVHD in all organs without CR
and without worsening in any organ. CR and overall response
(OR5CR1PR) occurred in 102 (36%) and 167 (60%), respectively.
Adjusting for differences between groups, factors favorably associ-
ated with achieving CR included use of non-myeloablative condi-
tioning (RR 2.1 vs 1.0 for myeloablative conditioning [95% CI,
1.2–3.6, p 5 .03]), onset of acute GVHD later than day 130 (RR
3.4 vs 1.0 for earlier onset [95% CI, 1.9–5.8, p\ .01]), grade II-III GVHD (RR 21.4 vs 1.0 for grade IV GVHD [95% CI, 2.8–
165.2, p\ .01]) and single organGVHD (RR 2.1 vs 1.0 for multiple
organ GVHD [95% CI, 1.2–3.6, p\ .01]). These factors were also
associated with OR. Probability of survival at 6 months after initia-
tion of steroid therapy was 64% (95%CI 59–69%) for the entire co-
hort. In Cox regression, factors associated with lower 6 month
mortality were use of UCB (RR 0.6 vs 1.0 for BM [95% CI, 0.4–
0.9, p 5 .02]), and grade II-III acute GVHD (RR of death 0.4 vs
1.0 for grade IV [95% CI, 0.3–0.7, p\ .01]). While mortality was
less in recipients of UCB, more effective GVHD therapy is needed
for patients with multiple organ involvement and for those with
grade IV acute GVHD regardless of HSC source.341
ALLOGENEIC ANTIBODIES SPECIFICALLY TARGET AML ANTIGEN NU-
SAP1 AFTER BONE MARROW TRANSPLANTATION
Wadia, P.P., Coram, M., Butte, A., Miklos, D.B. Stanford University,
Stanford, CA.
Allo-antibody (allo-ab) responses that develop after an allogeneic
hematopoietic cell transplant (HCT) in sex-mismatch transplant
patients are associated with cGVHD, persist even after 2 years
post-transplant and are quantitative.We hypothesize that novel mi-
nor histocompatibility antigens (mHA) can be serologically identi-
fied as targets of allo-ab responses that develop after an allogeneic
HCT. For this study, plasma was collected from five AML patients
one year post-transplant, pre-transplant, and from their donors and
detected against 5,000 full-length human proteins with N-terminal
GST epitopes presented on V3.0 ProtoArrayTM (Invitrogen). Tar-
gets of allo-Ab were identified after subtracting the pre-transplant
fluorescent signal intensities from their one-year plasma results
and then characterized for donor plasma response. New allo-Ab re-
sponses targeted 60–75 antigens with fluorescent differences rang-
ing 0.5 to 3 logs.
Two of the five patients showed Nucleolar and Spindle Associ-
ated Protein 1 (NuSAP1) and Chromatin Assembly Factor 1b
(CHAF1b) as the two predominant proteins recognized after
HCT. Exon DNA sequencing has failed to identify SNPs encoding
disparate amino acid polymorphisms. However gene expression
profiles showed NuSAP1 was up-regulated in AML as compared
to other types of leukemia. Therefore we hypothesize the allo-ab
immune response targets NuSAP1 due to increased expression as
a tumor associated antigen. We directly confirmed using RT-
PCR that NuSAP1 expression was the highest in AML peripheral
blood lymphocytes (Table attached) as compared to all other cell
populations sorted from GM-CSF mobilized peripheral blood
from healthy donors. To identify if antibodies specifically recog-
nized and targeted the potential tumor antigenNuSAP1 post-trans-
plant, 87 patients were screened by ELISA for allo-ab responses
against NuSAP1. Allo-ab against NuSAP1 were significantly higher
in patients post-transplant with AML (n5 27) as compared to ALL,
CLL, CML, MCL, MM and NHL, with a significance of p 5
0.0011 for NuSAP1 using Wilcox test.
NuSAP1 and CHAF1b were also highly expressed on
CD341Thy11 stem cells from healthy donors by RT-PCR.
ELISA results demonstrated that patients post-transplant also de-
veloped allo-ab responses to CHAF1b though these responses
were not significantly associated with disease. Taken together this
data suggests that allo-ab target tumor antigens and molecules
highly expressed in the hematopoietic stem cells.Relative mRNA expression
when normalized to ActinCell Populations NuSAP1 CHAF1bPatient AML PBSC (n 5 5) 17.06827 0.27725
Cell Populations from
healthy donors
CD341/THY11 (n 5 4) 9.297199 0.621888
CD3 (n 5 7) 2.243828 0.201833
CD19 (n 5 5) 2.030201 0.371341
PBSC (n 5 11) 2.950317 0.086726
